HBK Sorce Advisory’s AstraZeneca AZN Stock Holding History

HBK Sorce Advisory’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$735K	Buy	+4,017	New	+$775K	0.01%	300
2025 Q4	–	Sell	-3,893	Closed	-$660K	–	632
2025 Q3	$660K	Sell	3,893 -9	-0.2%	-$1.36K	0.02%	299
2025 Q2	$545K	Buy	3,902 +46	+1%	+$6.45K	0.01%	324
2025 Q1	$567K	Buy	3,856 +12	+0.3%	+$1.74K	0.02%	312
2024 Q4	$504K	Sell	3,844 -219	-5%	-$30.7K	0.02%	335
2024 Q3	$633K	Sell	4,063 -351	-8%	-$56.7K	0.02%	289
2024 Q2	$688K	Buy	4,414 +165	+4%	+$24.8K	0.02%	270
2024 Q1	$576K	Buy	4,249 +98	+2%	+$13K	0.02%	309
2023 Q4	$559K	Sell	4,151 -43	-1%	-$5.59K	0.02%	295
2023 Q3	$568K	Buy	4,194 +24	+0.6%	+$3.28K	0.03%	286
2023 Q2	$597K	Sell	4,170 -86	-2%	-$12.7K	0.03%	291
2023 Q1	$591K	Sell	4,256 -4,687	-52%	-$631K	0.03%	294
2022 Q4	$1.21M	Buy	8,943 +2,282	+34%	+$286K	0.03%	254
2022 Q3	$672K	Buy	6,661 +985	+17%	+$125K	0.05%	210
2022 Q2	$750K	Sell	5,676 -1,534	-21%	-$201K	0.06%	190
2022 Q1	$957K	Sell	7,210 -1,985	-22%	-$238K	0.05%	204
2021 Q4	$1.07M	Buy	9,195 +171	+2%	+$20.1K	0.05%	205
2021 Q3	$1.08M	Buy	9,024 +1,076	+14%	+$125K	0.06%	196
2021 Q2	$952K	Buy	7,948 +1,426	+22%	+$156K	0.05%	205
2021 Q1	$649K	Sell	6,522 -733	-10%	-$73.7K	0.04%	250
2020 Q4	$725K	Sell	7,255 -1,274	-15%	-$135K	0.04%	224
2020 Q3	$935K	Sell	8,529 -1,397	-14%	-$155K	0.07%	181
2020 Q2	$1.05M	Buy	9,926 +6,692	+207%	+$691K	0.08%	165
2020 Q1	$289K	Buy	3,234 +761	+31%	+$71.6K	0.03%	298
2019 Q4	$247K	Buy	+2,473	New	+$233K	0.02%	372
2018 Q2	–	Sell	-3,033	Closed	-$212K	–	390
2018 Q1	$212K	Sell	3,033 -120	-4%	-$8.31K	0.03%	343
2017 Q4	$219K	Buy	+3,153	New	+$213K	0.03%	352

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

HBK Sorce Advisory's AZN Position: Q1 2026 in Review

HBK Sorce Advisory opened a new position in AstraZeneca (AZN) in Q1 2026: 4,017 shares worth $735K. The stake represents 0.01% of the portfolio and ranks #300 among its holdings. This is a return to the name: HBK Sorce Advisory previously reported a position in AZN as recently as Q3 2025.

HBK Sorce Advisory first reported a position in AZN in Q4 2017 and has held it in 27 quarters since. The position peaked at $1.21M in Q4 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

HBK Sorce Advisory held 4,017 shares of AstraZeneca worth $735K as of Q1 2026.
AstraZeneca was a new HBK Sorce Advisory position in Q1 2026.
AstraZeneca made up 0.01% of HBK Sorce Advisory's portfolio in Q1 2026, its #300 holding.
HBK Sorce Advisory first reported a position in AstraZeneca in Q4 2017 and has held it in 27 quarters since.
HBK Sorce Advisory's AstraZeneca position peaked at $1.21M in Q4 2022.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.